Jupiter Topco LLC Takes Position in Xeris Biopharma Holdings, Inc. $XERS

Key Points

• Jupiter Topco LLC acquired 414,959 Xeris Biopharma shares worth approximately $3.29 million, giving it a 0.23% stake. Institutional investors and hedge funds collectively own 42.75% of the company.
• Xeris insiders sold 275,998 shares worth about $2.16 million over the past 90 days, although the reported transactions were conducted under pre-arranged Rule 10b5-1 trading plans.
• Analyst sentiment is mixed, with an average “Hold” rating and a $12 target price; Barclays raised its target to $12, while other firms downgraded the stock. Xeris reported quarterly revenue of $92.1 million, above estimates, but missed earnings expectations with a loss of $0.18 per share.

Jupiter Topco LLC acquired a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 414,959 shares of the company's stock, valued at approximately $3,287,000. Jupiter Topco LLC owned 0.23% of Xeris Biopharma as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in XERS. Kestra Advisory Services LLC acquired a new position in Xeris Biopharma in the fourth quarter worth about $25,000. KBC Group NV acquired a new stake in Xeris Biopharma during the first quarter valued at approximately $27,000. Allworth Financial LP bought a new stake in shares of Xeris Biopharma in the 2nd quarter valued at approximately $34,000. State of Wyoming bought a new stake in shares of Xeris Biopharma in the 2nd quarter valued at approximately $52,000. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of Xeris Biopharma by 9,276.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company's stock worth $59,000 after buying an additional 7,421 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Xeris Biopharma

In other news, insider Beth Hecht sold 16,666 shares of the company's stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $8.03, for a total transaction of $133,827.98. Following the transaction, the insider owned 1,161,128 shares of the company's stock, valued at $9,323,857.84. This represents a 1.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of Xeris Biopharma stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $6.09, for a total value of $97,440.00. Following the completion of the sale, the director owned 126,500 shares of the company's stock, valued at approximately $770,385. The trade was a 11.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 275,998 shares of company stock worth $2,157,809 over the last ninety days. 4.35% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Wall Street Zen downgraded Xeris Biopharma from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Barclays boosted their target price on shares of Xeris Biopharma from $9.00 to $12.00 and gave the company an "overweight" rating in a research note on Thursday, August 20th. Finally, Weiss Ratings cut shares of Xeris Biopharma from a "hold (c-)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Xeris Biopharma has an average rating of "Hold" and an average target price of $12.00.

Xeris Biopharma Trading Down 0.1%

XERS opened at $8.43 on Wednesday. Xeris Biopharma Holdings, Inc. has a 1-year low of $5.25 and a 1-year high of $10.08. The stock has a market capitalization of $1.54 billion, a PE ratio of -76.64 and a beta of 0.66. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00. The firm has a 50-day moving average price of $8.34 and a two-hundred day moving average price of $6.95.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%.The company had revenue of $92.10 million for the quarter, compared to analyst estimates of $90.12 million. As a group, equities analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current fiscal year.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source